Effect of Simvastatin on recurrence of endometriosis

Comparing the effect of Simvastatin and gonadotropin-releasing hormone agonist to prevent recurrence of endometriosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201009123384N5

Enrollment

Registered

2010-12-25

Start date

2010-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometrium

Interventions

Intervention 1: GNRH agonist group: 4 doses of Decapeptyle injection. Intervention 2: Simvastatin group: one tablet of 20mg Simvastatin per day.

Treatment - Drugs

GNRH agonist group: 4 doses of Decapeptyle injection

Simvastatin group: one tablet of 20mg Simvastatin per day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who have laparoscopy and their histological result is endometriosis. Exclusion criteria: Patients who don’t like to do laparoscopy or take drug.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Recurrence of endometriosis. Timepoint: First & 6 months after treatment. Method of measurement: Laparoscopy.	—

Secondary

Measure	Time frame
Severity of dyspareunia. Timepoint: the day after operation and one month after termination of medical treatment. Method of measurement: Visual Analog Scale.;Pelvic pain. Timepoint: the day after operation and one month after termination of medical treatment. Method of measurement: Visual Analog Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFariba Almasi

Iran University of Medical Sciences

dralmassi@yahoo.com+98 21 6655 5447

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026